IN8Bio, a University of Alabama spinout and cancer immunotherapy developer, has pulled in $40m through its IPO.

IN8Bio, a US-based cancer immunotherapy developer spun out of University of Alabama at Birmingham, has raised $40m in an initial public offering. The company issued 4 million shares on the Nasdaq Global Market priced at $10 each, which was the lower end of its initial $10 to $12 range. IN8Bio’s shares were trading at $7.10…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.